

MRD flow cytometry excellence – beyond cell identification, toward prognostic insights

Standardized workflow	Trusted data analysis	Dedicated scientific support	Expert review
Tightly controlled from staining to acquisition	By trained and licensed clinical laboratory scientists	Tailored for your program's success	By board-certified hematopathologists

Now available: AML NanoMRD™

Transforming AML MRD: minimal sample, maximum confidence, faster decisions.

An ELN-compliant, off-the-shelf, single-tube solution designed to deliver high-sensitivity MRD detection from low-input samples, supporting reliable, decision-ready data across clinical development.

Key capabilities

 Comprehensive spectral coverage • 23-color panel spanning myeloid, lymphoid, and stem cell populations for precise disease characterization	 Rapid turnaround • 3 days: Accelerate data availability for time-sensitive development milestones
 Optimized for limited sample input • Reliable performance with limited and precious samples • Bone marrow: 3-5 mL • Peripheral blood: 5-10 mL	 Hemodilution-adjusted analysis • Minimizes false negatives • Greater confidence in MRD assessment
 High sensitivity • 0.01% (10^{-4}): Detect MRD with confidence	 Advanced immunophenotypic profiling • Integrated LAIP and DfN identification and correlation for deeper biological and prognostic insight

Clinical and development impact

- De-risk AML programs with reproducible, high-confidence MRD insights
- Enable earlier go/no-go decisions based on relapse risk and treatment response
- Support robust MRD monitoring even with low-volume or challenging samples



Additional LDT validated off-the-shelf MRD assays

Assay	Cell type	Sample types	Sensitivity
B-ALL MRD	Lymphocytes, CD45 dim, detection of residual B-lymphoblasts	Bone marrow or peripheral blood in EDTA or sodium heparin tubes	0.01%
CLL MRD (Mod ERIC protocol)	Lymphocytes, detection of residual CLL cells		0.01%
MM MRD	Lymphocytes, normal/abnormal plasma cells, intracellular light chain restriction evaluation, detection of residual malignant plasma cells		0.001%

To learn more about our MRD flow cytometry offerings, contact us at **866.776.5907, option 3**, or **ContactPharma@NeoGenomics.com**.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England.



9490 NeoGenomics Way
Fort Myers, FL 33912
Phn: 866.776.5907
Fax: 239.690.4237

NeoGenomics.com

©2026 NeoGenomics Laboratories, Inc. All rights reserved.
All trademarks are the property of their respective owners.
CORP-MRKT-0351 07.26